Pharmaceutical Executive July 2018

July 2018 | Volume 38, Issue 7
Pharmaceutical Executive July 2018
From the Editor
With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?
Issue PDF
By Pharmaceutical Executive Editors
Click the title above to open the Pharmaceutical Executive July 2018 issue in an interactive PDF format.
Outlining a real-world case study in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”
Pharm Exec convenes an expert panel to discuss new ways to navigate the many complexities of assessing business and risk in the life sciences.
PharmExec talks to Dr. Gil Van Bokkelen, co-founder of Athersys, a company looking to forge new advances in the stem cell arena.
The role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).
Kevin J. Slatkavitz discusses how navigating compliance risks requires so much more than policies and procedures.
Streamlined clinical research, more guidance speed new cures to patients. Jill Wechsler reports.
Peter Young explores the prospects—and related challenges—for Chinese life science as it aggressively pursues new growth areas.
Special Sponsored Section
The Indian pharmaceutical industry is traditionally known as a global powerhouse for the production of bulk drugs and generics, but less heralded is the growth India has made on the pharma world stage in several other areas, including biotechnology and R&D.
lorem ipsum